Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) currently has a daily average trading volume of 585.35K but it saw 804175 shares traded on Thursday. With a market cap of 339.09M USD, stock’s current market price of $5.99 came falling about -1.96 while comparing to the previous closing price of $6.11. In past 52 weeks, the stock remained buoying in the range of price level as high as $11.90 and as low as $5.75. In the recent trading on the day, stock has struck highest price mark of $6.32 while lowest mark touched by it was $5.97.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Taking a look at 20-day trading activity of Vanda Pharmaceuticals Inc. (VNDA) gives us an average price of $6.39, while its current price level is -49.66% below from 52-week high level whereas it is 4.17% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $6.51 while that of 200 days or SMA-200 reads an average of $8.36. A closer look into the stock’s movement over the week reveals that its volatility is standing at 3.40% during that period while stretching the period over a month that increases to 4.47%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 38.26 which implies that the stock is in neutral territory.
Vanda Pharmaceuticals Inc. (VNDA)’s stock is currently under the radar of 1 analysts who are in consensus at a 12-month price target range of between $7.00 and $7.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $7.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $7.00. Average price target assigned by them is $7.00 which highlights an upside potential of 14.43% for the stock over that period. And to attain the median price target of $7.00 assigned by those analysts, stock has to add about 14.43% of value to its current levels.
Data by FactSet Research shows that 1 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 0 analysts suggested the investors to Buy the stock while 1 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Hold for the stock and that issued by Wall Street to investors is Hold.
Over the week, VNDA’s stock price is moving -1.96% down while it is -4.77% when we observe its performance for the past one month. Year-to-date it is -18.94% down and over the past year, the stock is showing a downside performance of -37.73%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2022, when its quarterly earnings per share (EPS) of $0.12 beat the consensus estimate of $0.08 for the same. The company is expected to be releasing its next quarterly report in 08/02/2023, for which analysts forecasted an EPS of $0 while estimate for next year EPS is -$0.44. For VNDA, analysts are forecasting an EPS-growth rate of -500.00% for current year and estimate for EPS growth in next year is -115.90%. In next quarter, company is expected to be making quarterly sales of $49 million as analysts are expecting the sales for current fiscal year at $211.9 million and seeing the company making $185.3 million in sales next year.
Currently, Vanda Pharmaceuticals Inc.’s total number of outstanding shares is 57.01M with 3.97% of that held by the insiders while 100.16% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 0.20% and return on equity (ROE) at 3.10%. It has a price to earnings ratio (P/E ratio) of 21.70. Stock’s beta reads 0.68. Stock has a price to book (P/B) ratio of 0.64 while price to sale or P/S ratio amounts to 1.32. Its return on asset (ROA) is 2.50% on average.
A filing at the U.S. Securities and Exchange Commission revealed that iShares Core S&P Small Cap ETF came shrinking its share ownership by -0.16% in the Vanda Pharmaceuticals Inc. (VNDA) decreasing its stake to 7.26% with control over 6630.0 shares in the company. As per SEC documents, iShares Core S&P Small Cap ETF sought 4,123,120 of company’s common stock of worth $25.32 million as per recent closing price of the stock. iShares Core S&P Small Cap ETF is not the only institutional holder which restructured its stake in Vanda Pharmaceuticals Inc., as SPDR S&P Biotech ETF picked 1,981,552 shares of worth $12.17 million to bring its holdings to a total of 34650.0 shares. In the most recent quarter, Vanguard Total Stock Market ETF came cutting its stake by -0.04% in the company and now holds 1.72 million or 3.03% of the company’s stake having worth of about 10.57 million.
